

해외 바이오의약품 임상 현황 (2020.2.17~2020.2.23)

한국바이오의약품협회, 2020.2.25.
출처: ClinicalTrials.gov

○ 미국 10건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04259450	Study to Assess AFM24 in Advanced Solid Cancers	Advanced Solid Tumor	Drug: AFM24	Affimed GmbH	Phase 1 Phase 2
NCT04277546	Open-label Extension Study of Brazikumab in Ulcerative Colitis	Ulcerative Colitis	Biological: Brazikumab	Allergan	Phase 2
NCT04221542	Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	Prostate Cancer	Drug: AMG 509 Drug: Dexamethasone	Amgen	Phase 1
NCT04196491	A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)	Multiple Myeloma	Biological: bb2121 carfilzomib Drug: Fludarabine Drug: Cyclophosphamide Drug: Lenalidomide	Celgene	Phase 1
NCT04081337	A Study to Measure Food and Calorie Consumption in Very Overweight Participants Using Tirzepatide	Obesity	Drug: Tirzepatide Drug: Placebo	Eli Lilly and Company	Phase 1
NCT04210115	Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)	Esophageal Squamous Cell Carcinoma (ESCC) Siewert Type I Adenocarcinoma of the Esophagogastric Junction (EGJ) Esophageal Adenocarcinoma (EAC)	Biological: pembrolizumab Drug: placebo Drug: cisplatin Drug: 5-FU Radiation: radiotherapy Drug: leucovorin Drug: levoleucovorin Drug: oxaliplatin	Merck Sharp & Dohme Corp.	Phase 3
NCT03929601	Rituximab and Abatacept for Prevention or Reversal of Type 1 Diabetes	Type 1 Diabetes Mellitus	Drug: Rituximab Drug: Abatacept	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH) Juvenile Diabetes Research Foundation	Phase 2
NCT04152863	Efficacy, Safety, and Tolerability of V937 Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)	Advanced/Metastatic Melanoma	Biological: V937 IV Biological: V937 IT Drug: Pembrolizumab	Merck Sharp & Dohme Corp.	Phase 2
NCT04261075	IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oclelumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	Biological: IPH5201 Biological: durvalumab Biological: oclelumab	MedImmune LLC	Phase 1
NCT04228783	A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants	Ebola	Biological: Ad26.ZEBOV Biological: MVA-BN-Filo Biological: Placebo	Janssen Vaccines & Prevention B.V.	Phase 3

○ 영국 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03996473	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Carcinoma, Non-Small-Cell Lung	Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Drug: Pembrolizumab	Bayer	Phase 1 Phase 2

○ 프랑스 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04261075	IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oclelumab in Subjects With Advanced Solid Tumors	Advanced Solid Tumors	Biological: IPH5201 Biological: durvalumab Biological: oclelumab	MedImmune LLC	Phase 1

○ 독일 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT03996473	Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases	Carcinoma, Non-Small-Cell Lung	Drug: Radium-223 dichloride (Xofigo, BAY 88-8223) Drug: Pembrolizumab	Bayer	Phase 1 Phase 2

○ 중국 2건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04213248	Effect of UMSCs Derived Exosomes on Dry Eye in Patients With cGVHD	Dry Eye	Drug: Umbilical Mesenchymal Stem Cells derived Exosomes	Zhongshan Ophthalmic Center, Sun Yat-sen University	Phase 1 Phase 2
NCT04280224	NK Cells Treatment for Novel Coronavirus Pneumonia	Novel Coronavirus Pneumonia	Biological: NK Cells	Xinxiang medical university First Affiliated Hospital of Xinjiang Medical University	Phase 1

○ 일본 1건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases
NCT04269538	Evaluation of Safety, Tolerability and Pharmacokinetics of Single Dose of PF-06480605 in Japanese Healthy Participants	Healthy	Drug: PF-06480605 Drug: Placebo	Pfizer	Phase 1